Search research articles
Contact Us
Filters
Showing results (271-280 of 320) with videos related to
Page
of 32
Sort By:
Ecancermedicalscience
|
January 26, 2012
The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update
L R Silverman, P Fenaux, G J Mufti, et al.
Leukemia
|
April 24, 1999
A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Français des Myélodysplasies. Group Ouest-Est d'étude des Leucémies aiguës myéloïdes
E Wattel, E Solary, X Leleu, et al.
Bone Marrow Transplantation
|
March 1, 2005
Allogeneic stem cell transplantation in second rather than first complete remission in selected patients with good-risk acute myeloid leukemia
A de Labarthe, C Pautas, X Thomas, et al.
Leukemia Research
|
July 20, 2018
Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A
C Kelaidi, T Braun, R Arana, et al.
Leukemia Research
|
August 2, 2011
Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS
S Park, R Sapena, C Kelaidi, et al.
Ecancermedicalscience
|
January 26, 2012
Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update
P Fenaux, G J Mufti, E Hellström-Lindberg, et al.
Blood
|
October 1, 1996
A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group
E Wattel, A Guerci, B Hecquet, et al.
Leukemia Research
|
August 4, 2018
The IPSS-R has prognostic impact in untreated patients with MDS del(5q)
J Kaivers, M Lauseker, B Hildebrandt, et al.
British Journal of Haematology
|
May 10, 2006
High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study
L Mannone, C Gardin, M C Quarre, et al.
Leukemia Research
|
December 20, 2011
Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?
R Itzykson, S Thépot, O Beyne-Rauzy, et al.
Page
of 32
Search research articles
Search
Showing results (271-280 of 320) with videos related to
Sort By:
Page
of 32
Ecancermedicalscience
|
January 26, 2012
The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update
L R Silverman, P Fenaux, G J Mufti, et al.
Leukemia
|
April 24, 1999
A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Français des Myélodysplasies. Group Ouest-Est d'étude des Leucémies aiguës myéloïdes
E Wattel, E Solary, X Leleu, et al.
Bone Marrow Transplantation
|
March 1, 2005
Allogeneic stem cell transplantation in second rather than first complete remission in selected patients with good-risk acute myeloid leukemia
A de Labarthe, C Pautas, X Thomas, et al.
Leukemia Research
|
July 20, 2018
Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A
C Kelaidi, T Braun, R Arana, et al.
Leukemia Research
|
August 2, 2011
Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS
S Park, R Sapena, C Kelaidi, et al.
Ecancermedicalscience
|
January 26, 2012
Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update
P Fenaux, G J Mufti, E Hellström-Lindberg, et al.
Blood
|
October 1, 1996
A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group
E Wattel, A Guerci, B Hecquet, et al.
Leukemia Research
|
August 4, 2018
The IPSS-R has prognostic impact in untreated patients with MDS del(5q)
J Kaivers, M Lauseker, B Hildebrandt, et al.
British Journal of Haematology
|
May 10, 2006
High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study
L Mannone, C Gardin, M C Quarre, et al.
Leukemia Research
|
December 20, 2011
Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?
R Itzykson, S Thépot, O Beyne-Rauzy, et al.
Page
of 32